Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15308MR)

This product GTTS-WQ15308MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Allergic asthma, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15308MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7409MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ7911MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ12833MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ2360MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ5294MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ7087MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ8276MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ6880MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA E-6011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW